



TEXAS DEPARTMENT OF INSURANCE

Division of Workers' Compensation - Medical Fee Dispute Resolution (MS-48)

7551 Metro Center Drive, Suite 100, Austin, Texas 78744-1645

(512) 804-4000 | F: (512) 804-4811 | (800) 252-7031 | TDI.texas.gov | @TexasTDI

MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

GENERAL INFORMATION

Requestor Name

Memorial Compounding RX

Respondent Name

Qbe Insurance Corporation

MFDR Tracking Number

M4-16-2183-01

Carrier's Austin Representative

Box Number 19

MFDR Date Received

March 28, 2016

REQUESTOR'S POSITION SUMMARY

Requestor's Position Summary: "The bill has each ingredient with the correct NDC numbers that make up the compound cream."

Amount in Dispute: \$994.36

RESPONDENT'S POSITION SUMMARY

Respondent's Position Summary: The Division placed a copy of the Medical Fee Dispute Resolution request in the insurance carrier's Austin representative box, which was acknowledged, received on April 5, 2016. The insurance carrier did not submit a response for consideration in this review. Per the Division's former rule at 28 Texas Administrative Code §133.307(d)(1), "If the Division does not receive the response information within 14 calendar days of the dispute notification, then the Division may base its decision on the available information." Accordingly, this decision is based on the available information.

SUMMARY OF FINDINGS

Dates of Service	Disputed Services	Amount In Dispute	Amount Due
October 15, 2015 October 29, 2015	Mefenamic Acid, Baclofen, Flurbiprofen, Meloxicam Mometasone Furoate, Levocetirizine, Tranilast, Gabapentin	\$994.36	\$994.36

FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

Background

- 28 Texas Administrative Code §133.307 sets out the procedures for resolving medical fee disputes.
- 28 Texas Administrative Code §134.530 sets out requirements for pharmacy services not subject to certified networks.
- 28 Texas Administrative Code §134.503 sets out the fee guidelines for pharmacy services not subject to a certified network.

4. The insurance carrier reduced payment for the disputed services with the following claim adjustment codes:
 - D20 – Previously denied by adjuster with PBM
 - 18 – Duplicate charge
 - D39 – A total breakdown of the compound medication is required. Please include the NDC number, actual milligrams for each ingredient, the dosage
 - 350 – Bill has been identified as a request for reconsideration or appeal

Issues

1. Is the carrier's denial supported?
2. What is the applicable rule and fee guideline that pertains to the services in dispute?
3. Based on applicable fee schedule is payment due?

Findings

1. The carrier denied the disputed services as D20 – "Previously denied by adjuster with PBM" 28 Texas Administrative Code 134.530 (b) states,

Preauthorization for claims subject to the Division's closed formulary.

(1) Preauthorization is only required for:

(A) drugs identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates;

(B) any compound that contains a drug identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates; and

(C) any investigational or experimental drug for which there is early, developing scientific or clinical evidence demonstrating the potential efficacy of the treatment, but which is not yet broadly accepted as the prevailing standard of care as defined in Labor Code §413.014(a).

28 Texas Administrative Code 134.530 (d) states,

Treatment guidelines. Except as provided by this subsection, the prescribing of drugs shall be in accordance with §137.100 of this title (relating to Treatment Guidelines), the division's adopted treatment guidelines.

(1) Prescription and nonprescription drugs included in the division's closed formulary and recommended by the division's adopted treatment guidelines may be prescribed and dispensed without preauthorization.

(2) Prescription and nonprescription drugs included in the division's closed formulary that exceed or are not addressed by the divisions' adopted treatment guidelines may be prescribed and dispensed without preauthorization.

(3) Drugs included in the closed formulary that are prescribed and dispensed without preauthorization are subject to retrospective review of medical necessity and reasonableness of health care by the insurance carrier in accordance with subsection (g) of this section.

Pursuant to provisions of Rule 134.530 (b) and (d), as none of the services in dispute, were found to have a Status "N" at the ODG Appendix A, authorization was not required prior to dispensing of medication and no evidence was found to support a retrospective review in accordance with 134.530(d) was conducted. The carrier's denial is not supported.

2. 28 Texas Administrative Code §134.503(c)(1)states,

The insurance carrier shall reimburse the health care provider or pharmacy processing agent for prescription drugs the lesser of:

(1) the fee established by the following formulas based on the average wholesale price (AWP) as reported by a nationally recognized pharmaceutical price guide or other publication of pharmaceutical pricing data in effect on the day the prescription drug is dispensed:

(A) Generic drugs: $((\text{AWP per unit}) \times (\text{number of units}) \times 1.25) + \4.00 dispensing fee per prescription = reimbursement amount;

(B) Brand name drugs: $((\text{AWP per unit}) \times (\text{number of units}) \times 1.09) + \4.00 dispensing fee per prescription = reimbursement amount;

(C) When compounding, a single compounding fee of \$15 per prescription shall be added to the calculated total for either paragraph (1)(A) or (B) of this subsection

The total allowable reimbursement will be calculated based on the submitted NDC and reported units as follows:

Date of Service	Prescribed Medication	Units	Amount billed	Total units per bottle	MAR (AWP) x units x 1.25 + \$4.00
October 15, 2015	Mefenamic Acid	2 grams	\$146.90	1 gm	$123.60000 \times 2 \times 1.25 + \$4.00 = \$158.50$
October 15, 2015	Baclofen	3 grams	\$102.60	1000 gm per jar	$1000 \text{ gm} \div 35.63 = 0.04 \text{ per gram} \times 3 = \$0.12 \times 1.25 = \$0.15 + \$4.00 = \$4.15$
October 15, 2015	Flurbiprofen	6 grams	\$210.90	1000 gm per bottle	$1000 \text{ gm} \div 36.58 = 0.04 \text{ per gram} \times 6 = \$0.24 \times 1.25 = \$0.30 + \$4.00 = \$4.30$
October 15, 2015	Meloxicam	0.18 gram	\$35.04	10 gm per bottle	$10 \text{ gm} \div 194.67 = \$19.47 \text{ per gram} \times 0.18 = \$3.50 \times 1.25 = \$4.38 + \$4.00 = \$8.38$
October 29, 2015	Mometasone Furoate	0.06 gram	\$274.86	1 gm per bottle	$\$12,566.0000 \times 0.06 = \$754 \times 1.25 = \$943.00 + \$4.00 = \$947.00$
October 29, 2015	Levocetirizine Dihydrochl	1.2 grams	\$98.28	1 gm per bottle	$84.77 \times 1.2 = \$102.00 \times 1.25 = \$128.00 + \$4.00 = \132.00
October 29, 2015	Tranilast Powder	1.8 grams	\$18.05	500 gm per bottle	$500 \text{ GM} \div 10.032 = \$0.02 \text{ per gram} \times 1.8 = \$0.04 \times 1.25 = \$0.05 + \$4.00 = \$4.05$
October 29, 2015	Gabapentin	1.8 grams	\$107.73	1000 gm per bottle	$1000 \div 59.85 = \$0.06 \text{ per gram} \times 1.8 = \$0.11 \times 1.25 = \$0.14 + \$4.00 = \$4.14$
			Total		\$1,262.52

3. The requestor states, "The bill has each ingredient with the correct NDC numbers that make up the compound cream." The MAR was calculated based on the reported number of units and the allowable per unit from the NDC description of total units per bottle and or jar. The total allowable based on the submitted claims' NDC numbers and units dispensed, is \$1,262.52. The requestor is seeking \$994.36. Pursuant to applicable fee guidelines this amount is allowed.

Conclusion

For the reasons stated above, the Division finds that the requestor has established that additional reimbursement is due. As a result, the amount ordered is \$994.36.

ORDER

Based upon the documentation submitted by the parties and in accordance with the provisions of Texas Labor Code Sections 413.031 and 413.019 (if applicable), the Division has determined that the requestor is entitled to additional reimbursement for the services in dispute. The Division hereby ORDERS the respondent to remit to the requestor the amount of \$994.36 plus applicable accrued interest per 28 Texas Administrative Code §134.130 due within 30 days of receipt of this Order.

Authorized Signature

Signature

Medical Fee Dispute Resolution Officer

Date

May , 2016

YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with 28 Texas Administrative Code §133.307, 37 *Texas Register* 3833, applicable to disputes filed on or after June 1, 2012.

A party seeking review must submit a **Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision** (form **DWC045M**) in accordance with the instructions on the form. The request must be received by the Division within **twenty** days of your receipt of this decision. The request may be faxed, mailed or personally delivered to the Division using the contact information listed on the form or to the field office handling the claim.

The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed with the Division. **Please include a copy of the *Medical Fee Dispute Resolution Findings and Decision*** together with any other required information specified in 28 Texas Administrative Code §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.